CKM is a fully human mAb anti-IL-1β that belongs to the IgG1/kappa isotype; it binds to the IL-1 beta (IL-1β); its purpose is to prevent its link with IL-1R avoid the inflammatory effects of IL-1 and is used to treat AR and sJIA [90,93,94]. The gene discussed is IL1B; the disease is systemic-onset juvenile idiopathic arthritis.